Is Intercept Pharmaceuticals Stock a Buy?

Treating nonalcoholic steatohepatitis (NASH), or metabolic liver disorders, is an area of significant interest for biotechnology companies. Indeed, the global prevalence of NASH is estimated at between 1.5% and 6.5% of the population. In the U.S., this number is even higher, with 3% to 12% of adults being affected by the condition, amounting to 8 million to 30 million people.

Due to this high prevalence, the total addressable market worldwide for treating NASH is estimated to be north of $35 billion. Let's look at one company that is making headlines in the NASH treatment market: Intercept Pharmaceuticals (NASDAQ: ICPT).

A diseased liver. Image source: Getty Images.

Continue reading

Source Fool.com